Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
29
VIR Quote, Financials, Valuation and Earnings
Last price:
$7.39
Seasonality move
:
61.66%
Day range:
$7.15 - $7.45
52-week range:
$6.56 - $13.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.14x
P/B ratio:
0.82x
Volume:
413.5K
Avg. volume:
1.5M
1-year change:
-27%
Market cap:
$1B
Revenue:
$39.5M
EPS (TTM):
-$3.92
Analysts' Opinion
-
Consensus RatingVir Biotechnology has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.25, Vir Biotechnology has an estimated upside of 299.73% from its current price of $7.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $7.38.
Fair Value
-
According to the consensus of 5 analysts, Vir Biotechnology has 299.73% upside to fair value with a price target of $31.25 per share.
VIR vs. S&P 500
-
Over the past 5 trading days, Vir Biotechnology has underperformed the S&P 500 by -2.47% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vir Biotechnology does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vir Biotechnology has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Vir Biotechnology reported revenues of $289K.
Earnings Growth
-
Vir Biotechnology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Vir Biotechnology reported earnings per share of -$1.56.
Enterprise value:
101.9M
EV / Invested capital:
0.08x
Price / LTM sales:
16.14x
EV / EBIT:
--
EV / Revenue:
1.64x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-0.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$61.1M
Return On Assets:
-29.88%
Net Income Margin (TTM):
-859.73%
Return On Equity:
-35.62%
Return On Invested Capital:
-35.62%
Operating Margin:
-75637.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.4B | $51.7M | $62M | -$4.1M | $289K | |
| Gross Profit | $2.2B | $43.7M | $61.1M | -$4.1M | $239K | |
| Operating Income | $1.6B | -$687.1M | -$578.8M | -$183.4M | -$218.6M | |
| EBITDA | $1.6B | -$670.1M | -$562.6M | -$178.8M | -$215.7M | |
| Diluted EPS | $8.49 | -$4.49 | -$3.92 | -$1.22 | -$1.56 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $849.6M | $1.1B | $2.4B | $1.8B | $1B | |
| Total Assets | $943.3M | $1.2B | $2.7B | $2B | $1.5B | |
| Current Liabilities | $77M | $233.7M | $308.2M | $165.1M | $117.2M | |
| Total Liabilities | $130.9M | $333.9M | $546.1M | $369.8M | $257.6M | |
| Total Equity | $812.4M | $876.3M | $2.1B | $1.7B | $1.2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.6B | -$635.7M | -$466.6M | -$155.8M | -$171.5M | |
| Cash From Investing | -$1.4B | $116.3M | $253.8M | -$59M | $118.6M | |
| Cash From Financing | $38.4M | $7.8M | $4.8M | $277K | $31K | |
| Free Cash Flow | $1.6B | -$668.3M | -$473.1M | -$159.5M | -$173.8M | |
VIR
Sector
Market Cap
$1B
$46.1M
Price % of 52-Week High
56.38%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-27%
-30.52%
Beta (5-Year)
0.492
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$7.37
200-day SMA
Sell
Level
$8.87
Bollinger Bands (100)
Sell
Level
7.31 - 8.73
Chaikin Money Flow
Sell
Level
-63.3M
20-day SMA
Sell
Level
$7.82
Relative Strength Index (RSI14)
Sell
Level
44.40
ADX Line
Sell
Level
14.18
Williams %R
Neutral
Level
-80
50-day SMA
Sell
Level
$8.01
MACD (12, 26)
Sell
Level
-0.21
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Sell
Level
-18.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.0279)
Sell
CA Score
(Annual)
Level (-0.4945)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (0.429)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Stock Forecast FAQ
In the current month, VIR has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The VIR average analyst price target in the past 3 months is $31.25.
-
Where Will Vir Biotechnology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vir Biotechnology share price will rise to $31.25 per share over the next 12 months.
-
What Do Analysts Say About Vir Biotechnology?
Analysts are divided on their view about Vir Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vir Biotechnology is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Vir Biotechnology's Price Target?
The price target for Vir Biotechnology over the next 1-year time period is forecast to be $31.25 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is VIR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vir Biotechnology is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of VIR?
You can purchase shares of Vir Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vir Biotechnology shares.
-
What Is The Vir Biotechnology Share Price Today?
Vir Biotechnology was last trading at $7.39 per share. This represents the most recent stock quote for Vir Biotechnology. Yesterday, Vir Biotechnology closed at $7.38 per share.
-
How To Buy Vir Biotechnology Stock Online?
In order to purchase Vir Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
